作者
Michael Tamilia, Nora Al-Kahtani, Louise Rochon, Michael P Hier, Richard J Payne, Christina A Holcroft, Martin J Black
发表日期
2011/3/1
期刊
Nuclear medicine communications
卷号
32
期号
3
页码范围
212-220
出版商
LWW
简介
Background
Most patients with differentiated thyroid cancer are treated with radioiodine (131-I) after thyroidectomy. The characteristics predictive of successful remnant ablation with low activities of 131-I are ill defined and could help stratify patients into those who should receive higher activities.
Methods
In a case series of 193 consecutive patients with papillary thyroid cancer who underwent total thyroidectomy and received 30 mCi (1110 MBq) of 131-I, we assessed the percentage of successful radioremnant ablation as defined by a composite of scintigraphic and biochemical endpoints. Clinical, histological, scintigraphic, and biochemical covariables were analyzed to identify associations with treatment failure.
Results
Successful radioremnant ablation with low-activity 131-I was obtained in 78% of the entire cohort of patients. The presence of limited microscopic extrathyroidal extension, nodal micrometastases, or an …
引用总数
20112012201320142015201620172018201920202021202220232024253102867213341